Hodgkins Lymphoma

Anaplastic large-cell lymphoma, T/null cell, primary systemic type Hodgkin s Lymphoma (Hodgkin s Disease)... [Pg.1374]

Cancers Multiple myeloma Non-Hodgkin s lymphoma Hodgkin s disease Acute myeloid leukemia Neuroblastoma Germ cell tumors Acute myeloid leukemia Acute lymphoblastic leukemia Chronic myeloid leukemia Myelodysplastic syndrome Myeloproliferative disorders Non-Hodgkin s lymphoma Hodgkin s disease Chronic lymphocytic leukemia Multiple myeloma... [Pg.1448]

Low- and intermediate-grade non-Hodgkin s lymphoma Hodgkin s disease... [Pg.1486]

Leukemia, lymphoma, Hodgkin s disease, or multiple myeloma / Generalized malignancy / Chronic renal failure of nephritic syndrome / Patients receiving immunosuppressive therapy / Organ or bone marrow transplant recipients... [Pg.586]

Said, J. W., Stoll, P. N., Shintaku, P., Bindl, J. M., Butmarc, J. R., and Pinkus, G. S., Leu-22 A preferential marker for T-lymphocytes in paraffin sections. Staining profile in T- and B-cell lymphomas, Hodgkin s disease, other lymphoproliferative disorders, myeloproliferative diseases, and various neoplastic processes. Am. J. Clin. Pathol. 91, 542-549 (1989). [Pg.348]

Therapeutic modalities in cancer treatment may involve surgery, radiation, and/or chemotherapy. The objectives of cancer chemotherapy include (1) cure, (2) reduction in tumor size, and (3) prolongation of life. At the present time, approximately 50 percent of patients with cancer can be cured, with drug treatment estimated to contribute in 17 percent of cases. Cancer chemotherapy can be curative in testicular cancer, diffuse large cell lymphoma, Hodgkin s disease, choriocarcinoma, certain childhood tumors (acute lymphoblastic leukemia, Burkitt s lymphoma, Wilms tumor, and embryonal rhabdomyosarcoma). Certain cancers are more resistant to chemotherapy than others (e.g., lung and colon). [Pg.177]

Autologous transplantation is commonly used in non-Hodgkin s lymphoma, Hodgkin s disease, multiple myeloma, and a relatively small subset of patients with solid tumors. A number of laboratory techniques are evolving to allow the bone marrow harvested for autologous transplantation to expand in the laboratory prior to infusion and to cleanse the marrow of potential malignant ceU contamination. [Pg.1801]

Acute lymphocytic leukemia Burkitt s lymphoma Hodgkin s lymphoma Choriocarcinoma (gestational trophoblastic neoplasm)... [Pg.2290]

Type Lymphoma Hodgkin Lymphoma Lymphoma Lymphoma Lymphoma... [Pg.148]

Hodgkin s disease Malignant lymphomas, Hodgkin s disease, multiple myeloma, leukemia, carcinoma of the ovary and breast, neuroblastoma, retinoblastoma Testicular cancer... [Pg.584]

CD52 Lymphoma Hodgkin s lymphoma (Reed-Stemberg cells) B- and T-lymphocytes, monocytes, germ cells... [Pg.61]

Factors inhibiting cell division can be present in the serum from patients with tuberculosis, sarcoidosis, lymphomas, Hodgkin s disease, and various solid tumors... [Pg.221]

Vascular tmnors Angiosarcoma Hemangiosarcoma Epithelioid hemangioendothelioma Leiomyosarcoma Fibrosarcoma Embryonal sarcoma Fibrous histiocytoma Lymphoma (Hodgkin s disease) Lymphoma (non-Hodgkin s disease)... [Pg.239]

This alkylating agent acts on the haemo-poietic system, and particularly pronounced on the lymphoid series. It has been found to be effective in chronic lymphatic leukaemia, the non-Hodgkin lymphomas, Hodgkin s disease and in macroglobulinaemia. On the whole toxicity is slight, gastrointestinal intolerance is relatively uncommon and bone marrow depression is a late unavoidable complication. [Pg.341]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...